News

Podcast

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Author(s):

Alexandra Gerlach, Associate Editor

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Asthma COPD Breath Nebulizer And Mask Given By Doctor Or Nurse - Image credit: Angelov | stock.adobe.com
Hematology -- Image credit: DIgilife | stock.adobe.com
Related Content
Diffuse large B cell lymphoma (DLBCL) -- Image credit: SuriyaPhoto | stock.adobe.com
July 18th 2025

FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL

Gillian McGovern, Associate Editor
COBRRA Trial Results Raise Questions About VTE Management
July 15th 2025

COBRRA Trial Results Raise Questions About VTE Management

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
LDL Receptor, Cholesterol Management (3D Rendering)
July 18th 2025

Polypurine Hairpin Technology is Safe, Effective at Inhibiting PCSK9 to Regulate Cholesterol

Luke Halpern, Assistant Editor
Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike
July 10th 2025

Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike

Gustavo Alva, MD Luke Halpern, Assistant Editor
NCCN Flash Update: Updated CML Guidelines Emphasize Distress Screening, Drug Interactions, and Cost
July 18th 2025

NCCN Flash Update: Updated CML Guidelines Emphasize Distress Screening, Drug Interactions, and Cost

Alana Hippensteele, Lead Editor
NCCN Flash Update: Linvoseltamab Added as Preferred Regimen After 4 Prior Therapies for Multiple Myeloma
July 18th 2025

NCCN Flash Update: Linvoseltamab Added as Preferred Regimen After 4 Prior Therapies for Multiple Myeloma

Alana Hippensteele, Lead Editor